A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Photobiomodulation Under Electroencephalographic Controls of Sleep for Stimulation of Lymphatic Removal of Toxins from Mouse Brain

1.7K views

⸱

DOI:

10.3791/67035

⸱

June 28th, 2024

 ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , 
1Department of Biology, Saratov State University, 2Institute of Physics, Department of Optics and Biophotonics, Saratov State University, 3Institute of Biochemistry and Physiology of Plants and Microorganisms, Saratov Scientific Centre of the Russian Academy of Sciences

In This Article

Summary

This study presents an original and portable tPBM technology under electroencephalographic (EEG) control of deep or non-rapid eye movement (NREM) sleep in non-anesthetized male C57BL/6 mice of different ages to stimulate lymphatic clearance of Aβ from the brain into the peripheral lymphatic system (the deep cervical lymph nodes, dcLNs).

Abstract

The meningeal lymphatic vessels (MLVs) play an important role in the removal of toxins from the brain. The development of innovative technologies for the stimulation of MLV functions is a promising direction in the progress of the treatment of various brain diseases associated with MLV abnormalities, including Alzheimer's and Parkinson's diseases, brain tumors, traumatic brain injuries, and intracranial hemorrhages. Sleep is a natural state when the brain's drainage processes are most active. Therefore, stimulation of the brain's drainage and MLVs during sleep may have the most pronounced therapeutic effects. However, such commercial technologies do not currently exist.

This study presents a new portable technology of transcranial photobiomodulation (tPBM) under electroencephalographic (EEG) control of sleep designed to photo-stimulate removal of toxins (e.g., soluble amyloid beta (Aβ)) from the brain of aged BALB/c mice with the ability to compare the therapeutic effectiveness of different optical resources. The technology can be used in the natural condition of a home cage without anesthesia, maintaining the motor activity of mice. These data open up new prospects for developing non-invasive and clinically promising photo-technologies for the correction of age-related changes in the MLV functions and brain's drainage processes and for effectively cleansing brain tissues from metabolites and toxins. This technology is intended both for preclinical studies of the functions of the sleeping brain and for developing clinically relevant treatments for sleep-related brain diseases.

Introduction

Meningeal lymphatic vessels (MLVs) play an important role in the removal of toxins and metabolites from brain tissues1,2,3. Damage of MLVs in various brain diseases, including tumors, traumatic brain injuries, hemorrhages, and neurodegenerative processes, is accompanied by a decrease in the MLV functions leading to the progression of these pathologies1,2,3,4,5,6. Therefore, the development of methods for the stimulation of MLVs opens new horizons in the emergence of effective technologies for the treatment of brain diseases. Recently, non-invasive technology for effective transcranial photobiomodulation (tPBM) has been proposed to stimulate MLVs and remove toxins such as blood and Aβ from the brain5,7,8,9,10,11,12. It is interesting to note that deep sleep is a natural factor for the activation of lymphatic drainage processes in the brain13,14. Based on this fact, it is logical to assume that the tPBM of MLVs during sleep may have more effective therapeutic effects than during wakefulness9,11,12,15. However, there are currently no commercial technologies for tPBM during sleep16. In addition, animal experiments to study the therapeutic effects of tPBM are performed under anesthesia, which is required to accurately deliver light to the brain. However, anesthesia significantly affects the brain's drainage, which reduces the quality of research results17.

Aβ is a metabolic product of normal neural activity18. As it was established in cultured rat cortical neurons, Aβ is released from them at high rates into the extracellular space (2-4 molecules/neuron/s for Aβ)19. There is evidence that the dissolved form of Aβ, located in the extracellular and perivascular spaces, is most toxic to neurons and synapses20. The soluble Aβ is rapidly cleared from the human brain during 1-2.5 h21. MLVs are the tunnels for removal of the soluble Aβ from the brain1,7 that declines with age, leading to the accumulation of Aβ in the aged brain1,22. There is evidence that extracellular abnormalities of Aβ levels in the brain correlate with cognitive performance in aging and are associated with the development of Alzheimer's disease (AD)23,24. Therefore, aged and old rodents are considered alternatives to transgenic models for the study of amyloidosis, including AD25,26.

This study presents an original and portable tPBM technology under electroencephalographic (EEG) control of deep or non-rapid eye movement (NREM) sleep in non-anesthetized male C57BL/6 mice of different ages to stimulate lymphatic clearance of Aβ from the brain into the peripheral lymphatic system (the deep cervical lymph nodes, dcLNs).

Access restricted. Please log in or start a trial to view this content.

Protocol

All procedures were performed in accordance with the "Guide for the Care and Use of Laboratory Animals", Directive 2010/63/EU on the Protection of Animals Used for Scientific Purposes, and the guidelines from the Ministry of Science and High Education of the Russian Federation (Nº 742 from 13.11.1984), which have been approved by the Bioethics Commission of the Saratov State University (Protocol No. 7, 22.09.2022).

1. Hardware assembly

  1. Cut a piece of foil textolite that is 1.5 mm thick to the dimensions of 1.5 mm x 2 mm. This part will be referred to as the light-emitting diode (LED) printed circuit board (PCB) (Figure 1C).
  2. Solder an LED to a PCB, as shown in Figure 1.
  3. Solder two stranded copper wires to the pins of an LED and then cover them with a sleeve.
  4. Print out the 3D model of the frame (Figure 1A); place an LED (Figure 1B) and magnets (Figure 1D) on the frame; place a washer (Figure 1E) on the mouse's head.
  5. To assemble the circuit (Figure 2), follow these steps.
    1. First, connect the resistor (Figure 2; R1) between an LED anode and 5 V port on the Arduino.
    2. Next, connect an LED cathode to the metal-oxide-semiconductor field-effect transistor (MOSFET) (Figure 2; Q1) drain. Then, connect the MOSFET source to the ground.
    3. Connect the pull-down resistor (Figure 2; R2) between the MOSFET gate and the ground. Finally, connect the MOSFET gate to pin 3 on the Arduino.
  6. Connect a liquid crystal display (LCD) keypad shield to the Arduino.
  7. Print out the 3D models of the case, the cover plate, and the buttons. Insert the Arduino board with LCD keypad shield, MOSFET, and LED connector into the case, as shown in Figure 3.

2. Software guide (Figure 4)

  1. Download the Arduino sketch (.ino file) and open it via the Arduino integrated development environment (IDE) (Supplementary Coding File 1).
  2. Select the correct communication (COM) port and flash the firmware.
  3. The interface includes two columns. Use the buttons Left and Right to navigate between these columns. The selection indicator is located to the left of the column.
  4. The left-hand column on the screen is the pulse width modulation (PWM) duty cycle selection field. Use the Up and Down buttons to adjust the duty cycle. Achieve the 10/20/30 Dj/cm2 dose of PBM with a corresponding 2%/4%/6% PWM duty cycle in a 17 min session.
  5. The right-hand column on the screen is the RUN/Off field. To select this column, press the Right button on the keypad and then press Select. When the process is running, the activity indicator will blink, and the text on the RUN button will change to OFF.
    NOTE. Mice are prepared for the experiments over a period of 10 days, including implantation of EEG electrodes, implantation of a chronic catheter into the right lateral ventricle for injection of fluorescent Aβ, and placement of a plate for PBM.

3. Implantation of an EEG recording system (Figure 5)

  1. Weigh the mouse and anesthetize it with a mixture of Ketamine and Xylazine (100 mg/kg; 10 mg/kg, respectively) by intramuscular injection into the thigh. Administer Xylazine as pre-operative analgesia at a concentration of 20 mg/mL at a dose of 1.5 mL/kg.
  2. When the rear foot withdrawal reflexes and tail pinch response cease, place the mouse in a stereotaxic frame over a heating pad (Figure 5A).
  3. Apply ophthalmic ointment to the eyelids to prevent drying of the eyeballs during surgery. Repeat this procedure whenever necessary.
  4. Shave the head in the area from the nasal bones to the occipital bones using a shaving machine and disinfect the exposed skin with alternating rounds of chlorhexidine and alcohol 3 times each.
  5. Using straight dissecting scissors, cut off the scalp, hold it with micro forceps, clean the skull from fascia, and dry it with cotton swabs. If necessary, use the hemostatic agents.
  6. Using a drill with a diameter of 1.3 mm, make 2 holes in the temporal bones on each side along the coordinates: AP = -1 mm for the first pair of screws and AP = -3 mm for the second pair of screws.
  7. Place the EEG screws with wire leads in alcohol for 15 min. Afterward, place the EEG screws in the saline solution.
  8. Place four silver-plated screws with electrodes into the holes to a depth of 1 mm (Figure 5B).
  9. Fix the screws on the surface of the skull using dental acrylic so that the electrodes extending from them are located towards the animal's nose (Figure 5C). Allow the dental acrylic to harden for 15 min.
  10. Attach an EEG recording sensor to the animal's nose using dental acrylic. Allow the dental acrylic to harden for 30 min (Figure 5D).
  11. Place the EMG electrodes on the back of the orbicularis oculi muscle using curved tweezers and fix them with the dental acrylic. Allow the dental acrylic to harden for 15 min (Figure 5E).
  12. Connect the EEG electrodes to the silver-plated recess of the sensor and solder them using a soldering station. Afterward, fix the EEG electrodes using the dental acrylic (Figure 5F).
  13. After surgery, place the mouse on a heating pad to maintain body temperature until the animal fully recovers from anesthesia.
  14. Afterward, put the mouse in an individual home cage with free access to food and water with ibuprofen (40 mg/kg in 200 mL of water) for analgesia after surgery for 10 days.
    NOTE: Each animal was kept in an individual cage so that the mice could not deform the EEG registration system. Ibuprofen was supplied with water to prevent stress in animals.

4. Implantation of a plate for PBM

  1. Weigh the mouse and anesthetize it with a mixture of Ketamine and Xylazine (100 mg/kg; 10 mg/kg, respectively) by intramuscular injection into the thigh 7 days after implantation of the EEG recording system. Administer Xylazine as pre-operative analgesia at a concentration of 20 mg/mL at a dose of 1.5 mL/kg.
  2. When the rear foot withdrawal reflexes and tail pinch response cease, fix the mouse in a stereotactic system.
  3. Apply ophthalmic ointment to the eyelids to prevent drying of the eyeballs during surgery. Repeat this procedure whenever necessary.
  4. Fix a metal plate with a diameter of 5 mm on the occipital bone of the skull using dental acrylic and Dumont forceps. Allow the dental acrylic to harden for 15 min (Figure 6).

5. Preparation of a chronic catheter

  1. Mark on the insulin needle a segment 2 cm from the side of the beveled end.
  2. Fix the insulin needle in the needle holder from the side of the beveled tip to the marked segment.
  3. Place a 2 cm-PE-10 polyethylene catheter over the entire remaining length of the needle.
  4. Fill the catheter with a saline solution and cover it with a plastic cap to seal it.

6. Implantation of a chronic catheter into the right lateral ventricle

  1. After implantation of the plate for PBM, make a trepanation hole at the coordinates AP = -0.5 mm and ML = 1.2 mm, with a diameter of 1.5 mm, using a drill.
  2. Place the PE-10 polyethylene catheter in a stereotactic holder and insert it into the mouse skull (DV = 2 mm). Afterward, fix it using the dental acrylic. Allow the dental acrylic to harden for 15 min (Figure 7).
  3. After surgery, place the mouse on a heating pad to maintain body temperature until the animal fully recovers from anesthesia.
  4. Afterward, put the mouse in an individual home cage with free access to food and water with ibuprofen (40 mg/kg in 200 mL of water) for analgesia after surgery for 10 days.
    NOTE: Each animal was kept in an individual cage so that the mice could not deform the EEG registration system. Ibuprofen was supplied with water to prevent stress in animals. Apply antibacterial ointment to the exposed areas of the skull and soft tissues during the rehabilitation period (7 days) to prevent them from drying out.

7. tPBM under EEG control of NREM sleep

  1. Connect any commercial EEG recording system to the connector on the mouse's head and set the requirement value of the PWM duty cycle.
  2. Monitor the EEG signal and wait for delta rhythm activity. If NREM sleep is seen, initiate the PBM process and stop the process if NREM sleep transitions to rapid eye movement (REM) sleep or wakefulness. The dose increases with each interaction until it reaches the required value.
  3. When the required PBM dose is obtained, the session is over.

8. Confocal imaging of lymphatic removal of Aβ from mouse brain

  1. Connect a 10 cm catheter to an insulin needle.
  2. Using a Hamilton syringe with a 29 G needle, prepare an infusion of fluorescent beta-amyloid (FAβ) in a volume of 5 µL into the catheter. Let the catheter remain on a Hamilton syringe.
  3. Fix the mouse's hand and connect the catheter through a needle to the implanted chronic catheter.
  4. Connect the catheter to a microinjector. Afterward, place the mouse in an individual box;
  5. Select the injection rate 0.1 µL/min in the microinjector menu, and press the Start button.
  6. Make injection of FAβ into the right lateral ventricle.
  7. After FAβ administration, make PBM using an LED for 61 min following the algorithm: 17 min - light and 5 min - pause over 61 min.
  8. After PBM, intravenously inject any tracer for labeling the cerebral vessels via the tail.
  9. After injection, euthanize mice using the CO2 euthanasia chamber.
  10. Using sharp, straight scissors, make a small transverse incision in the skin along the trachea, holding the skin with straight non-sharp tweezers.
  11. Make a longitudinal incision along the entire length of the neck using straight scissors.
  12. Using curved tweezers, take up the salivary glands and carefully separate them from the connective tissue. Place a wound retractor on the open section of the incision and fix it in such a way as to push back the surrounding tissues.
  13. Examine the area between the trachea and the cleidomastoid muscle using two curved tweezers from both sides of the neck.
  14. When the deep cervical lymph node (dcLN) is detected on each side, take off dcLNs using straight tweezers with blunt ends and cut it from the connective tissue.
  15. Place dcLNs in a Petri dish with a saline solution and cover them with horizontally oriented cover glass (25 mm × 50 mm × 0.17 mm).
  16. Use any commercial confocal microscope to obtain images of whole dcLNs.

9. Analysis of Aβ in the lysates of brain tissues

  1. Prepare the samples for the assay.
    1. Euthanize mice using the CO2 euthanasia chamber.
    2. Decapitate the mouse, remove the skin from its head, and remove the muscles from the skull.
    3. Make two incisions with sharp, straight scissors from the great occipital foramen to the auditory canal.
    4. Using straight tweezers, separate the ventral part of the skull, the occipital bone, and bones forming the middle ear cavities.
    5. Using tweezers, separate the brain from the parietal and frontal bones.
    6. Using straight scissors, remove the upper jaw and cut off the olfactory bulbs.
    7. Place the brain in the physiological solution.
    8. Rinse the brain in cold phosphate-buffered saline to remove excess blood thoroughly and weigh before homogenization.
    9. Prepare a lysing buffer pH 7.2 containing 1.5 mm KH2PO4, 8 mm Na2HPO4, 3 mm KCl, 137 mm NaCl and 0.1% Tween20, 10 mM EDTA with a freshly prepared protease inhibitory mixture.
    10. Homogenize the brain in fresh lysis buffer (1 mL of lysis buffer for 200-500 mg tissue sample) with a glass homogenizer on ice.
    11. Sonicate a resulting suspension with an ultrasonic cell disruptor till the solution is clarified.
    12. Centrifuge the homogenates at 10,000 × g for 5 min.
    13. Collect the supernatant using a single channel mechanical pipette (100-1000 µL) and assay immediately or aliquot and store at ≤-20 °C.
  2. Prepare the following materials: microplate reader with 450 nm ± 10 nm filter; microcentrifuge tubes; single or multi-channel pipettes with high precision and disposable tips; absorbent paper for blotting the microplate; container for wash solution; 0.01 mol/L (or 1x) phosphate buffered saline (PBS); and deionized or distilled water.
  3. Prepare the reagents.
    1. Bring the components of the kit and samples to room temperature (RT; 18-25 °C) before use.
    2. Reconstitute the standard with the 1.0 mL of standard diluent, keep for 10 min at RT, and shake gently (not to foam). The standard stock solution is 300 pg/mL. Prepare 5 tubes containing a volume of 0.6 mL of standard diluent and make a triple dilution series.
    3. Set up 5 points (300 pg/mL, 100 pg/mL, 33.33 pg/mL, 11.11 pg/mL, and 3.70 pg/mL) of the diluted standard, and the last tubes with as blank containing only the standard diluent (0 pg/mL).
    4. Quickly spin down the stock solutions of Detection reagent A and Detection reagent B prior to use. Dilute them 100-fold with Assay Diluent A and B to prepare the working concentration.
    5. Dilute 20 mL of the concentrated wash solution (30x) with 580 mL of deionized or distilled water to make 600 mL of wash solution (1x).
    6. Aspirate the needed dosage of the solution with sterilized tips, and do not dump the residual solution into the vial again.
  4. Perform the assay.
    1. Determine wells for a diluted standard, blank, and sample.
    2. Prepare 5 wells for standard points and one well for blank.
      1. Add 50 µL each of standard, blank, and sample dilutions into the corresponding wells, respectively. Then, add 50 µL of Detection reagent A to each well immediately.
      2. Shake the plate gently (a microplate shaker is recommended) and cover it with a plate sealer. Incubate the plate at 37 °C for 1 h. Detection reagent A may appear cloudy. Warm the solution to RT and mix gently until it appears uniform.
    3. Aspirate the solution and wash each well with 350 µL of 1x wash solution with the help of a squirt bottle, multi-channel pipette, manifold dispenser, or auto washer. Leave the plate undisturbed for 1-2 min. Snap the plate onto absorbent paper to completely remove the remaining liquid from all wells. Repeat this procedure 3 times.
    4. After the last wash, aspirate or decant any remaining wash buffer. Ensure complete removal of the washing solution by inverting the plate and blotting it against absorbent paper.
    5. Add 100 µL of Detection reagent B working solution to each well and incubate the plate for 30 min at 37 °C after covering it with the plate sealer.
    6. Repeat the aspiration/washing steps for a total of 5 min.
    7. Add 90 µL of substrate solution to each well and cover the plate with a new plate sealer. Incubate for 10-20 min at 37 °C (Do not exceed 30 min) protected from light. After adding the substrate solution, the liquid will turn blue.
    8. Add 50 µL of a stop solution to each well to terminate the reaction. Adding the stop solution will turn the liquid yellow. Tap the plate on its side to mix the liquid. If the color change is inconsistent, gently tap the plate to ensure thorough mixing.
    9. Ensure complete removal of water and fingerprint on the bottom of the plate and no bubble formation on the liquid surface. Then, read the plate in a microplate reader at 450 nm immediately.
  5. Calculate the results.
    1. Determine the average of the duplicate readings for each standard, control, and sample. Plot a standard curve with the log of Aβ 1-42 concentration on the y-axis and absorbance on the x-axis.
    2. Draw a best-fit curve through the points, which can be determined by regression analysis.
    3. If diluted samples were used, multiply the concentration obtained from the standard curve by the dilution factor.
      NOTE: For ELISA, a kit for determining Aβ 1-42 was used in this study.

Access restricted. Please log in or start a trial to view this content.

Results

In the first step, the study has focused on establishing the effective light dose (a 1050 nm LED) for stimulation of lymphatic removal of fluorescent Aβ from the brain to dcLNs in awake adult (2-3 month old, 26-29 g) male BALB/c mice. The light doses were selected randomly as 10 J/cm2, 20 J/cm2, and 30 J/cm2 based on our previous studies of tPBM effects on the removal of different dyes and the red blood cells from the brain7,...

Access restricted. Please log in or start a trial to view this content.

Discussion

MLVs are an important target for the development of innovative technologies for modulation of the brain's drainage and removal of cellular debris and wastes from the brain, especially in aged subjects whose MLV function declines1,22. In a homeostatic state, deep sleep is associated with the natural activation of brain tissue cleansing13,14. Therefore, it is obvious to expect that stimulation of MLVs d...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This research was supported by a grant from the Russian Science Foundation (No. 23-75-30001).

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
0.1% Tween20Helicon,  RussiaSB-G2009-100ML
CatheterScientific Commodities Inc., USAPE-10, 0.28 mm ID × 0.61 mm OD
CO2 chamberBinder, GermanyCB-S 170
Confocal microscopNikon, JapanA1R MP
Dental acrylicZermack, Poland-RussiaVillacryl S, V130V4Z05
DrillForedom, RussiaSR W-0016
Dumont forcepsStoelting, USA52100-07
Evans Blue dyeSigma-Aldrich, St. Louis, MO, USA206334
HamiltonHamilton Bonaduz AG, Switzerland29 G needle
IbuprofenSintez OJSC, RussiaN/A Analgesic drug
Insulin needleINSUPEN, Italy31 G, 0.25 mm x 6 mm
Levomekol antibacterial ointmentNizhpharmD06C For external use at a dose of 40 mg/g, 1 time per day
Micro forcepsStoelting, USA52102-02P
MicrocentrifugeGyrozen, South KoreaGZ-1312
MicroinjectorStoelting, USA53311
Non-sharp tweezerStoelting, USA52108-83P
PINNACLE systemPinnacle Technology, USA8400-K3-SLSystem for recording EEG (2 channels) and EMG (1 channel) of mice
Shaving machineBraunSeries 3310s
Single and multi-channel pipettesEppendorf, AustriaEpp 3120 000.020, Epp 3122 000.019
Sodium chlorideKraspharma, RussiaN/A
Soldering stationAOYUE, ChinaN/A
Stereotaxic frameStoelting, USA51500
Straight dissecting scissorsStoelting, USA52132-10P
TetracyclineJSC Tatkhimfarmpreparaty, RussiaN/AEye ointment
TweezerStoelting, USA52100-03
Ultrasonic cell disrupterBiobase, ChinaUSD-500
Wound retractorStoelting, USA52125
XylanitNita-Farm, RussiaN/AMuscle relaxant
Zoletil 100Virbac Sante Animale, FranceN/AGeneral anesthesia

References

  1. Da Mesquita, S., et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease. Nature. 560 (7717), 185-191 (2018).
  2. Chen, J., et al. Meningeal lymphatics clear erythrocytes that arise from subarachnoid hemorrhage. Nat Commun. 11, 3159(2020).
  3. Zou, W., et al. Blocking meningeal lymphatic drainage aggravates Parkinson's disease-like pathology in mice overexpressing mutated α-synuclein. Transl Neurodegener. 8, 7(2019).
  4. Hu, X., et al. Meningeal lymphatic vessels regulate brain tumor drainage and immunity. Cell Res. 30 (3), 229-243 (2020).
  5. Dong-Yu, L., et al. Photostimulation of brain lymphatics in male newborn and adult rodents for therapy of intraventricular hemorrhage. Nat Comm. 14 (1), 6104(2023).
  6. Bolte, A., et al. Meningeal lymphatic dysfunction exacerbates traumatic brain injury pathogenesis. Nat Commun. 11 (1), 4524(2020).
  7. Semyachkina-Glushkovskaya, O., et al. Mechanisms of phototherapy of Alzheimer's disease during sleep and wakefulness: the role of the meningeal lymphatics. Front Optoelectron. 16, 22(2023).
  8. Dongyu, L., et al. Photostimulation of lymphatic clearance of β- amyloid from mouse brain: new strategy for the therapy of Alzheimer's disease. Front Optoelectron. 16, 45(2023).
  9. Semyachkina-Glushkovskaya, O., et al. Mechanisms of phototherapy of Alzheimer's disease during sleep and wakefulness: the role of the meningeal lymphatics. Front Optoelectron. 16, 22(2023).
  10. Semyachkina-Glushkovskaya, O., et al. Intranasal delivery of liposomes to glioblastoma by photostimulation of the lymphatic system. Pharmaceutics. 15 (1), 36(2023).
  11. Semyachkina-Glushkovskaya, O., et al. Night photostimulation of clearance of beta-amyloid from mouse brain: New strategies in preventing Alzheimer's disease. Cells. 10 (12), 3289(2021).
  12. Semyachkina-Glushkovskaya, O., et al. Technology of the photobiostimulation of the brain's drainage system during sleep for improvement of learning and memory in male mice. Biomed Opt Express. 15 (1), 44-58 (2024).
  13. Fultz, N., et al. Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep. Science. 366 (6465), 628-631 (2019).
  14. Xie, L., et al. Sleep drives metabolite clearance from the adult brain. Science. 342 (6156), 373-377 (2013).
  15. Semyachkina-Glushkovskaya, O., et al. Phototherapy of Alzheimer's disease: Photostimulation of brain lymphatics during sleep: A systematic review. Int J Mol Sci. 24 (13), 10946(2023).
  16. Semyachkina-Glushkovskaya, O., et al. Brain waste removal system and sleep: Photobiomodulation as an innovative strategy for night therapy of brain diseases. Int J Mol Sci. 24 (4), 3221(2023).
  17. Hablitz, L. M., et al. Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia. Sci Adv. 5 (2), 5447(2019).
  18. Fukumoto, H., et al. Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid beta peptides ending at A beta40 and A beta42. Neuroreport. 10 (14), 2965-2969 (1999).
  19. Moghekar, A., et al. Large quantities of Abeta peptide are constitutively released during amyloid precursor protein metabolism in vivo and in vitro. J Biol Chem. 286 (16), 15989-15997 (2011).
  20. Wells, C., Brennan, S., Keon, M., Ooi, L. The role of amyloid oligomers in neurodegenerative pathologies. Int J Biol Macromol. 181, 582-604 (2021).
  21. Savage, M., et al. Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci. 18 (5), 1743-1752 (1998).
  22. Ahn, J., et al. Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid. Nature. 572 (7767), 62-66 (2019).
  23. Stevens, D., et al. Regional amyloid correlates of cognitive performance in ageing and mild cognitive impairment. Brain Commun. 4 (1), 016(2022).
  24. Ma, C., Hong, F., Yang, S. Amyloidosis in Alzheimer's disease: Pathogeny, etiology, and related therapeutic directions. Molecules. 27 (4), 1210(2022).
  25. Kobro-Flatmoen, A., Hormann, T., Gouras, G. Intracellular amyloid-β in the normal rat brain and human subjects and its relevance for Alzheimer's disease. J Alzheimers Dis. 95 (2), 719-733 (2023).
  26. Ahlemeyer, B., Halupczok, S., Rodenberg-Frank, E., Valerius, K., Baumgart-Vogt, E. Endogenous murine amyloid-β peptide assembles into aggregates in the aged C57BL/6J mouse suggesting these animals as a model to study pathogenesis of amyloid-β plaque formation. J Alzheimers Dis. 61 (4), 1425-1450 (2018).
  27. Zhinchenko, E., et al. Pilot study of transcranial photobiomodulation of lymphatic clearance of beta-amyloid from the mouse brain: Breakthrough strategies for nonpharmacologic therapy of Alzheimer's disease. Biomed Opt Express. 10 (8), 4003-4017 (2019).
  28. Semyachkina-Glushkovskaya, O., et al. Transcranial photobiomodulation of clearance of beta-amyloid from the mouse brain: Effects on the meningeal lymphatic drainage and blood oxygen saturation of the brain. Adv Exp Med Biol. 1269, 57-61 (2021).
  29. Semyachkina-Glushkovskaya, O., et al. Photobiomodulation of lymphatic drainage and clearance: Perspective strategy for augmentation of meningeal lymphatic functions. Biomed Opt Express. 11 (2), 725-734 (2020).
  30. Zhinchenko, E., et al. Photostimulation of extravasation of beta-amyloid through the model of blood-brain barrier. Electronics. 9 (6), 1056(2020).
  31. Semyachkina-Glushkovskaya, O., et al. Photostimulation of cerebral and peripheral lymphatic functions. Transl Biophotonics. 2 (1-2), e201900036(2020).
  32. Semyachkina-Glushkovskaya, O., et al. Photomodulation of lymphatic delivery of liposomes to the brain bypassing the blood-brain barrier: New perspectives for glioma therapy. Nanophotonics. 10 (12), 3215-3227 (2021).
  33. Semyachkina-Glushkovskaya, O., et al. Photomodulation of lymphatic delivery of Bevacizumab to the brain: The role of singlet oxygen. Adv Exp Med Biol. 1395, 53-57 (2022).
  34. Semyachkina-Glushkovskaya, O., et al. Transcranial photosensitizer-free laser treatment of glioblastoma in rat brain. Int J Mol Sci. 24 (18), 13696(2023).
  35. Blázquez-Castro, A. Direct 1O2 optical excitation: A tool for redox biology. Redox Biol. 13, 39-59 (2017).
  36. Spitler, R., Berns, M. Comparison of laser and diode sources for acceleration of in vitro wound healing by low-level light therapy. J Biomed Opt. 19 (3), 038001(2014).
  37. Sato, K., Watanabe, R., Hanaoka, H., Nakajima, T., Choyke, P., Kobayashi, H. Comparative effectiveness of light emitting diodes (LEDs) and Lasers in near infrared photoimmunotherapy. Oncotarget. 7 (12), 14324-14335 (2016).
  38. Keshri, G., Gupta, A., Yadav, A., Sharma, S., Singh, S. Photobiomodulation with pulsed and continuous wave near-infrared laser (810 nm, Al-Ga-As) augments dermal wound healing in immunosuppressed rats. PLoS One. 11 (11), e0166705(2016).
  39. Kim, H., et al. Pulse frequency dependency of photobiomodulation on the bioenergetic functions of human dental pulp stem cells. Sci Rep. 7 (1), 15927(2017).
  40. Chen, Z., et al. The pulse light mode enhances the effect of photobiomodulation on B16F10 melanoma cells through autophagy pathway. Lasers Med Sci. 38 (1), 71(2023).
  41. Mezey, E., et al. An immunohistochemical study of lymphatic elements in the human brain. Proc Natl Acad Sci U S A. 118 (3), e2002574118(2021).
  42. Chang, J., et al. Characteristic features of deep brain lymphatic vessels and their regulation by chronic stress. Research. 6, 0120(2023).
  43. Prineas, L. W. Multiple sclerosis: Presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science. 203 (4385), 1123-1125 (1979).
  44. Semyachkina-Glushkovskaya, O., et al. Pilot identification of the Live-1/Prox-1 expressing lymphatic vessels and lymphatic elements in the unaffected and affected human brain. bioRxiv. , 458990(2021).
  45. Semyachkina-Glushkovskaya, O., Postnov, D., Kurths, J. Blood-brainbarrier, lymphatic clearance, and recovery: Ariadne's thread in labyrinths of hypotheses. Int J Mol Sci. 19 (12), 3818(2018).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Photobiomodulation TherapyMeningeal Lymphatic VesselsEEG Sleep MonitoringBrain DrainageAmyloid Beta RemovalTranscranial PBMConfocal MicroscopyNREM Sleep StimulationMouse Brain ToxinsNon-Invasive Brain Therapy
Photobiomodulation Under Electroencephalographic Controls of Sleep for Stimulation of Lymphatic Removal of Toxins from Mouse Brain
Contact Us
Recommend to Library

Privacy

Terms of Use

Policies

Copyright © 2026 MyJoVE Corporation. All rights reserved.